Amphastar Pharmaceuticals, Inc. Logo

Amphastar Pharmaceuticals, Inc.

AMPH

(2.8)
Stock Price

43,80 USD

18.7% ROA

25.42% ROE

13.59x PER

Market Cap.

2.252.716.024,00 USD

82.86% DER

0% Yield

23.36% NPM

Amphastar Pharmaceuticals, Inc. Stock Analysis

Amphastar Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amphastar Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (18.78%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

4 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

5 DER

The stock maintains a fair debt to equity ratio (90%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

7 Buffet Intrinsic Value

The company's stock seems undervalued (4.327) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

8 PBV

The stock's elevated P/BV ratio (4.59x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Amphastar Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amphastar Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Amphastar Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amphastar Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2011 118.356.000
2012 204.323.000 42.07%
2013 229.681.000 11.04%
2014 210.461.000 -9.13%
2015 251.519.000 16.32%
2016 255.165.000 1.43%
2017 240.175.000 -6.24%
2018 294.666.000 18.49%
2019 322.357.000 8.59%
2020 349.846.000 7.86%
2021 437.768.000 20.08%
2022 498.987.000 12.27%
2023 722.224.000 30.91%
2023 644.395.000 -12.08%
2024 729.576.000 11.68%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amphastar Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 31.049.000
2012 31.163.000 0.37%
2013 33.019.000 5.62%
2014 28.427.000 -16.15%
2015 37.065.000 23.31%
2016 41.199.000 10.03%
2017 43.415.000 5.1%
2018 57.564.000 24.58%
2019 68.853.000 16.4%
2020 67.229.000 -2.42%
2021 60.932.000 -10.33%
2022 74.771.000 18.51%
2023 66.656.000 -12.17%
2023 63.888.000 -4.33%
2024 58.136.000 -9.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amphastar Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 26.433.000
2012 27.223.000 2.9%
2013 30.972.000 12.1%
2014 34.809.000 11.02%
2015 41.504.000 16.13%
2016 41.832.000 0.78%
2017 44.458.000 5.91%
2018 49.888.000 10.88%
2019 50.279.000 0.78%
2020 50.377.000 0.19%
2021 51.434.000 2.06%
2022 45.061.000 -14.14%
2023 50.616.000 10.97%
2023 51.540.000 1.79%
2024 53.140.000 3.01%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amphastar Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2011 -20.086.000
2012 40.253.000 149.9%
2013 31.389.000 -28.24%
2014 -17.105.000 283.51%
2015 4.081.000 519.14%
2016 15.692.000 73.99%
2017 -6.181.000 353.87%
2018 -8.623.000 28.32%
2019 -39.000 -22010.26%
2020 10.954.000 100.36%
2021 69.887.000 84.33%
2022 107.497.000 34.99%
2023 290.712.000 63.02%
2023 241.464.000 -20.4%
2024 277.448.000 12.97%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amphastar Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2011 28.104.000
2012 90.303.000 68.88%
2013 86.956.000 -3.85%
2014 51.256.000 -69.65%
2015 77.347.000 33.73%
2016 104.189.000 25.76%
2017 90.795.000 -14.75%
2018 106.985.000 15.13%
2019 131.923.000 18.9%
2020 143.340.000 7.96%
2021 199.739.000 28.24%
2022 248.860.000 19.74%
2023 433.612.000 42.61%
2023 343.968.000 -26.06%
2024 368.192.000 6.58%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amphastar Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2011 7.752.000
2012 18.094.000 57.16%
2013 11.862.000 -52.54%
2014 -10.699.000 210.87%
2015 -2.787.000 -283.89%
2016 10.532.000 126.46%
2017 4.508.000 -133.63%
2018 -5.738.000 178.56%
2019 48.939.000 111.72%
2020 1.097.000 -4361.17%
2021 62.116.000 98.23%
2022 91.386.000 32.03%
2023 196.888.000 53.58%
2023 137.545.000 -43.14%
2024 151.796.000 9.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amphastar Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 1
2012 2 100%
2013 1 -100%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 1 100%
2020 0 0%
2021 1 100%
2022 2 0%
2023 4 75%
2023 3 -100%
2024 3 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amphastar Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2011 8.378.000
2012 -26.895.000 131.15%
2013 12.740.000 311.11%
2014 553.000 -2203.8%
2015 -5.366.000 110.31%
2016 17.178.000 131.24%
2017 4.110.000 -317.96%
2018 -8.617.000 147.7%
2019 207.000 4262.8%
2020 23.411.000 99.12%
2021 70.538.000 66.81%
2022 65.147.000 -8.28%
2023 145.337.000 55.18%
2023 54.141.000 -168.44%
2024 63.065.000 14.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amphastar Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 19.096.000
2012 -1.650.000 1257.33%
2013 31.042.000 105.32%
2014 21.052.000 -47.45%
2015 10.681.000 -97.1%
2016 38.560.000 72.3%
2017 39.209.000 1.66%
2018 38.191.000 -2.67%
2019 41.762.000 8.55%
2020 57.266.000 27.07%
2021 97.994.000 41.56%
2022 89.181.000 -9.88%
2023 183.503.000 51.4%
2023 64.334.000 -185.23%
2024 69.109.000 6.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amphastar Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 10.718.000
2012 25.245.000 57.54%
2013 18.302.000 -37.94%
2014 20.499.000 10.72%
2015 16.047.000 -27.74%
2016 21.382.000 24.95%
2017 35.099.000 39.08%
2018 46.808.000 25.01%
2019 41.555.000 -12.64%
2020 33.855.000 -22.74%
2021 27.456.000 -23.31%
2022 24.034.000 -14.24%
2023 38.166.000 37.03%
2023 10.193.000 -274.43%
2024 6.044.000 -68.65%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amphastar Pharmaceuticals, Inc. Equity
Year Equity Growth
2012 233.439.000
2013 251.545.000 7.2%
2014 281.860.000 10.76%
2015 295.510.000 4.62%
2016 329.255.000 10.25%
2017 337.329.000 2.39%
2018 364.359.000 7.42%
2019 427.528.000 14.78%
2020 448.723.000 4.72%
2021 445.522.000 -0.72%
2022 528.658.000 15.73%
2023 595.140.000 11.17%
2023 639.421.000 6.93%
2024 713.346.000 10.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amphastar Pharmaceuticals, Inc. Assets
Year Assets Growth
2012 317.477.000
2013 338.748.000 6.28%
2014 389.370.000 13%
2015 390.136.000 0.2%
2016 427.738.000 8.79%
2017 454.665.000 5.92%
2018 513.563.000 11.47%
2019 586.971.000 12.51%
2020 631.236.000 7.01%
2021 671.529.000 6%
2022 741.987.000 9.5%
2023 1.544.633.000 51.96%
2023 1.512.912.000 -2.1%
2024 1.491.522.000 -1.43%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amphastar Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2012 84.038.000
2013 87.203.000 3.63%
2014 107.510.000 18.89%
2015 94.626.000 -13.62%
2016 98.483.000 3.92%
2017 117.336.000 16.07%
2018 149.204.000 21.36%
2019 159.443.000 6.42%
2020 182.513.000 12.64%
2021 226.007.000 19.24%
2022 213.329.000 -5.94%
2023 949.493.000 77.53%
2023 873.491.000 -8.7%
2024 778.176.000 -12.25%

Amphastar Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
14.58
Net Income per Share
3.4
Price to Earning Ratio
13.59x
Price To Sales Ratio
3.16x
POCF Ratio
10.65
PFCF Ratio
12.65
Price to Book Ratio
3.17
EV to Sales
3.76
EV Over EBITDA
9.87
EV to Operating CashFlow
12.62
EV to FreeCashFlow
15.06
Earnings Yield
0.07
FreeCashFlow Yield
0.08
Market Cap
2,25 Bil.
Enterprise Value
2,68 Bil.
Graham Number
33.43
Graham NetNet
-8.14

Income Statement Metrics

Net Income per Share
3.4
Income Quality
1.28
ROE
0.25
Return On Assets
0.11
Return On Capital Employed
0.17
Net Income per EBT
0.82
EBT Per Ebit
0.88
Ebit per Revenue
0.32
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0.08
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.53
Operating Profit Margin
0.32
Pretax Profit Margin
0.28
Net Profit Margin
0.23

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
4.35
Free CashFlow per Share
3.64
Capex to Operating CashFlow
0.16
Capex to Revenue
0.05
Capex to Depreciation
0.62
Return on Invested Capital
0.15
Return on Tangible Assets
0.19
Days Sales Outstanding
67.28
Days Payables Outstanding
34.98
Days of Inventory on Hand
134.75
Receivables Turnover
5.42
Payables Turnover
10.44
Inventory Turnover
2.71
Capex per Share
0.7

Balance Sheet

Cash per Share
4,50
Book Value per Share
14,59
Tangible Book Value per Share
2.3
Shareholders Equity per Share
14.59
Interest Debt per Share
12.56
Debt to Equity
0.83
Debt to Assets
0.4
Net Debt to EBITDA
1.58
Current Ratio
3.52
Tangible Asset Value
0,11 Bil.
Net Current Asset Value
-0,30 Bil.
Invested Capital
1267095000
Working Capital
0,35 Bil.
Intangibles to Total Assets
0.4
Average Receivables
0,13 Bil.
Average Payables
0,03 Bil.
Average Inventory
118952500
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amphastar Pharmaceuticals, Inc. Dividends
Year Dividends Growth
2009 0
2010 0 0%

Amphastar Pharmaceuticals, Inc. Profile

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CEO
Dr. Yongfeng Zhang Ph.D.
Employee
1.761
Address
11570 6th Street
Rancho Cucamonga, 91730

Amphastar Pharmaceuticals, Inc. Executives & BODs

Amphastar Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Tony Marrs M.B.A., M.P.H., M.S.
Executive Vice President of Regulatory Affairs & Clinical Operations
70
2 Mr. William J. Peters M.B.A.
Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director
70
3 Mr. Dan Dischner M.B.A.
Senior Vice President of Human Resources & Corporate Communication
70
4 Dr. Ziping Luo Ph.D.
Chairman of the Board, Chief Scientist & Chief Operating Officer
70
5 Dr. Yongfeng Zhang Ph.D.
Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director
70
6 Mr. Jacob Liawatidewi M.B.A.
Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director
70
7 Mr. Rong Zhou M.S.
Senior EVice President of Production & EVP of Scientific Affairs
70

Amphastar Pharmaceuticals, Inc. Competitors